Authorised Therapeutic exploratory (Phase II) Alport Syndrome

A study to learn about how well BAY 3401016 works in adults with Alport syndrome

EU CTIS ID: 2024-516471-33-00

What this study is testing

Assess the effect of BAY 3401016 on albuminuria in participants with Alport syndrome

  • Therapeutic exploratory (Phase II)

A plain-language read of the study's public EU CTIS listing. The study team confirms the details.

Who can take part

You may be able to join if

  • Participants must be 18 to 45 years of age inclusive
  • Participants with AS, either XLAS (male) or ARAS (male or female)
  • eGFR ≥ 45 mL/min/1.73m2
  • UACR ≥ 500mg/g
  • Treatment with ACEi and/or ARB

You likely can't join if

  • Chronic kidney disease is different from AS
  • Clinically significant illness that could have influence on the safety of the participant and/or interfere with the study objectives
  • History or current existence of malignancy
  • Participants with history of severe allergies, multiple drug allergies or non-allergic drug reactions including allergies affecting the lower respiratory tract – allergic asthma, allergies requiring therapy with corticosteroids or urticaria
  • Participants with active skin disorders (e.g. atopic dermatitis, severe acne)
  • Systolic blood pressure above 140 mmHg
See the full eligibility criteria
Who can join
  • Participants must be 18 to 45 years of age inclusive
  • Participants with AS, either XLAS (male) or ARAS (male or female)
  • eGFR ≥ 45 mL/min/1.73m2
  • UACR ≥ 500mg/g
  • Treatment with ACEi and/or ARB
What rules you out
  • Chronic kidney disease is different from AS
  • Clinically significant illness that could have influence on the safety of the participant and/or interfere with the study objectives
  • History or current existence of malignancy
  • Participants with history of severe allergies, multiple drug allergies or non-allergic drug reactions including allergies affecting the lower respiratory tract – allergic asthma, allergies requiring therapy with corticosteroids or urticaria
  • Participants with active skin disorders (e.g. atopic dermatitis, severe acne)
  • Systolic blood pressure above 140 mmHg
  • Diastolic blood pressure above 90 mmHg

The study team makes the final eligibility decision.

Where it's taking place

  • Japan
  • India
  • United States
  • Canada
  • Argentina
  • China
  • United Kingdom
  • Korea, Republic of

Questions & answers

Do participants get paid in this trial?

This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.

Is it free to join, and do I need insurance?

Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.

How long does this study last?

The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.

Who can join this trial?

This study is enrolling all sexes, 18-64 years. The study team makes the final eligibility decision.

Where is this trial taking place?

Study sites include Japan; India; United States; Canada; Argentina; China and 2 more location(s). Enter your location above to see the nearest site and check your eligibility.

Explore other conditions

BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.